Alleged image fraud at MD Anderson Cancer Center (Bharat Aggarwal lab)

SUMMARY of alleged image fraud (+ other research misconduct)

2012-03-02T06:56:00.000+09:00

Bharat Aggarwal (MD anderson cancer center)
Article No.1 → Antioxid Redox Signal. 2012 Mar 1;16(5):413-27.
Article No.2 → Br J Pharmacol. 2012 Feb;165(3):741-53.
Article No.3 → Biochim Biophys Acta. 2012 Jan 10. [Epub ahead of print]
Article No.4 → J Biol Chem. 2012 Jan 2;287(1):245-56.
Article No.5 → Cancer Lett. 2011 Dec 17. [Epub ahead of print] (Withdrawn)
Article No.6 → Biochem Pharmacol. 2011 Dec 15;82(12):1901-9.
Article No.7 → Biochem Pharmacol. 2011 Nov 1;82(9):1134-44.

Article No.8 → Mol Pharmacol. 2011 Nov;80(5):889-99.
Article No.9 → Mol Pharmacol. 2011 Nov;80(5):769-81.

Article No.10 → Carcinogenesis. 2011 Sep;32(9):1372-80.
Article No.11 → Cancer Prev Res (Phila). 2011 Jul;4(7):1084-94.

Article No.12 → Int J Cancer. 2011 Jul 1;129(1):23-33.
Article No.13 → Carcinogenesis. 2011 Jun;32(6):904-12.

Article No.14 → Mol Pharmacol. 2011 Feb;79(2):279-89.
Article No.15 → J Biol Chem. 2011 Feb 18;286(7):5546-57.
Article No.16 → Cancer Res. 2011 Jan 15;71(2):538-49.

Article No.17 → J Biol Chem. 2011 Jan 14;286(2):1134-46.
Article No.18 → J Mol Med (Berl). 2010 Dec;88(12):1243-53.
Article No.19 → J Biol Chem. 2010 Nov 12;285(46):35418-27.
Article No.20 → J Biol Chem. 2010 Oct 22;285(43):33520-8.

Article No.21 → Mol Cancer Res. 2010 Oct;8(10):1425-36.
Article No.22 → Biochem Pharmacol. 2010 Oct 1;80(7):1021-32.
Article No.23 → J Biol Chem. 2010 Aug 27;285(35):26987-97.
Article No.24 → Mol Cancer Ther. 2010 Aug;9(8):2196-207.

Article No.25 → Biochem Pharmacol. 2010 Jun 1;79(11):1640-7.
Article No.26 → Mol Pharmacol. 2010 May;77(5):818-27.
Article No.27 → Int J Cancer. 2010 Jul 15;127(2):257-68.

Article No.28 → Mol Cancer Res. 2010 May;8(5):751-61.
Article No.29 → Mol Cancer Ther. 2010 Apr;9(4):856-68.
Article No.30 → Cancer Res. 2010 Mar 1;70(5):1951-9
Article No.31 → J Biol Chem. 2010 Apr 9;285(15):11498-507.
Article No.32 → Biochem Pharmacol. 2010 Jan 15;79(2):218-28
Article No.33 → Cancer Res. 2009 Dec 1;69(23):8958-66.
Article No.34 → Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42.
Article No.35 → Cancer Res. 2009 Aug 15;69(16):6581-9.
Article No.36 → Blood. 2009 Feb 26;113(9):2003-13.
Article No.37 → Cancer Res. 2009 Feb 15;69(4):1477-84.
Article No.38 → Mol Pharmacol. 2009 Mar;75(3):525-33.
Article No.39 → Mol Cancer Res. 2009 Jan;7(1):118-28.

Article No.40 → Cancer Res. 2008 Nov 1;68(21):8861-70.
Article No.41 → Mol Cancer Ther. 2008 Oct;7(10):3306-17.
Article No.42 → Cell Microbiol. 2008 Jul;10(7):1442-52.
Article No.43 → Mol Cancer Res. 2008 Jun;6(6):1059-70.
Article No.44 → Cancer Res. 2008 Jun 1;68(11):4406-15.
Article No.45 → Blood. 2008 May 15;111(10):4880-91.

Article No.46 → Mol Pharmacol. 2008 May;73(5):1549-57.
Article No.47 → Blood. 2007 Nov 15;110(10):3517-25.
Article No.48 → Oncogene. 2007 Nov 15;26(52):7324-32.
Article No.49 → Mol Cancer Res. 2007 Sep;5(9):943-55.
Article No.50 → Blood. 2007 Jun 15;109(12):5112-21.
Article No.51 → Clin Cancer Res. 2007 May 15;13(10):3024-32.
(Mol Cancer Ther. 2010 Feb;9(2):429-37.)
Article No.52 → Clin Cancer Res. 2007 Apr 1;13(7):2290-7.
Article No.53 → Biochem Pharmacol. 2007 Apr 1;73(7):1024-32.
Article No.54 → Blood. 2007 Apr 1;109(7):2727-35.

Article No.55 → Blood. 2007 Mar 15;109(6):2293-302.
Article No.56 →Oncogene. 2007 Mar 1;26(10):1385-97.
Article No.57 → Toxicology. 2006 Nov 10;228(1):1-15.
Article No.58 → J Immunol. 2006 Oct 15;177(8):5612-22.
Article No.59 → Mol Pharmacol. 2006 Jan;69(1):195-206.
Article No.60 → Clin Cancer Res. 2006 Jan 15;12(2):662-8.
Article No.61, 62, 63, 64, 65 → J Immunol. 2000 Nov 15;165(10):5962-9.
Cancer Res. 2000 Jul 15;60(14):3838-47.
  J Immunol. 2000 Jun 15;164(12):6509-19.
  J Immunol. 2000 Jun 1;164(11):5815-25.
    J Immunol. 1999 Dec 15;163(12):6800-9.

Retraction Watch

→ MD Anderson investigating researcher Bharat Aggarwal over images
→ Retraction WatchTracking retractions as a window into the scientific processMD Anderson researcher Aggarwal loses paper in Cancer Letters

Abnormal Science Blog
  →  Like Father Like Son?
  →  From the premier cancer center in the world-part 2
  →  From the premier cancer center in the world-part 3
  →  From the premier cancer center in the world-part 4
  → From the premier cancer center in the world-part 5

Gautam Sethi (National University of Singapore)
Abnormal Science Blog
→ Never mind the quality, feel the width

See also  → Alleged image fraud at the University of Tokyo
See also  → Alleged image fraud (Michael Karin lab et al.)
See also  → Alleged image manipulation (Yanagisawa lab at Tsukuba university)
See also  → Scientific misconduct at Tokyo Medical and Dental University (Akio Kawakami, MD)

ScienceInsider News   → Whistleblower Uses YouTube to Assert Claims of Scientific Misconduct

Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha.

2012-02-17T08:30:00.003+09:00

Oncogene. 2007 Nov 15;26(52):7324-32. Epub 2007 May 28.

Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha.

Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

gure 1C, 1D - b-actin loading control in lanes 1-4 of A, is the same as b-actin in D.

Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis.

2012-02-17T08:27:00.003+09:00

Mol Cancer Res. 2008 Jun;6(6):1059-70.

Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis.

Sethi G, Ahn KS, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Figure 6B - Panels B1 and B2, same images used for un-treated and TQ treated groups.

Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1.

2012-02-17T08:23:00.002+09:00

Mol Pharmacol. 2009 Mar;75(3):525-33. Epub 2008 Dec 22.

Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1.

Pandey MK, Sung B, Ahn KS, Aggarwal BB.

Source

Department of Experimental Therapeutics, Cytokine Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Figure 1D - Lanes 3 and 4 (10 and 25 dose) are identical to Figure 1G (SCC4 +/-)

Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.

2012-02-17T08:21:00.002+09:00

Mol Cancer Res. 2009 Jan;7(1):118-28.

Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.

Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, Unit 143, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Figure 2B - STAT3 loading control is identical in left and right panels (IL-6 vs. IL-6+AKBA).
Figure 4A, 4C, 5D - b-actin loading control is the same for all 3 panels.

Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.

2012-02-17T08:19:00.001+09:00

Cancer Res. 2009 Aug 15;69(16):6581-9. Epub 2009 Aug 4.

Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.

Yodkeeree S, Sung B, Limtrakul P, Aggarwal BB.

Source

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.

Figure 3B - DR5 siRNA. "Medium" and "Zerumbone + TRAIL" panels are identical.
Figure 5A - DR4 and DR5 blots, vertical seam between lanes 5 and 6.

Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.

2012-02-17T08:16:00.001+09:00

Biochem Pharmacol. 2010 Jan 15;79(2):218-28. Epub 2009 Aug 12.

Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.

Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM.

Source

Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, United States.

Figure 5A - TUNEL. Curcumin panel is the Vehicle panel, higher intensity and stretched horizontal.

Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.

2012-02-11T04:36:00.003+09:00

Cancer Res. 2009 Dec 1;69(23):8958-66. Epub 2009 Nov 10.

Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.

Kamat AM, Tharakan ST, Sung B, Aggarwal BB.

Source

Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. akamat@mdanderson.org

Fig. 1A, lower panels (curcumin treated), Medium ad PMN images (panels 1 and 3 in this row) are identical.

Fig. 5B. Curcumin (top right) and BCG (bottom left) have similar areas of image.

Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

2012-02-11T04:34:00.004+09:00

Int J Cancer. 2010 Jul 15;127(2):257-68.

Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S,Aggarwal BB.

Source

Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Fig. 1C. Counting from the top left, there are 16 panels. Panel #6 and #16 are identical. (11 and 50 are the numbers below these panels).

Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway.

2012-02-11T04:32:00.006+09:00

Mol Pharmacol. 2010 May;77(5):818-27. Epub 2010 Jan 26.

Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway.

Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB.

Source

Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Fig. 3E - LPS+Escin, and OA + Escin (lanes 9 and 11) are identical - enhance the contrast to see it.

Fig. 4B - this is a b-actin blot. It is IDENTICAL to a STAT3 loading control used in Figure 2C of PMID 17505005 (Clin Cancer Res. 2007 May 15;13(10):3024-32.). Something is erased from the top right coner in both images, so we know they're the same.

Fig. 6C - A293, b-actin control for TRADD in left side, is the same as b-actin control for p65 on the right side. Blot has been flipped horizontally between conditions.

Fig. 5B - b-actin control in TNF and TNF+Escin is the same, flipped horizontally. There are even vertical shear-lines on this image, so it is impossible to deny they are identical.

Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.

2012-02-11T04:30:00.003+09:00

J Biol Chem. 2010 Apr 9;285(15):11498-507. Epub 2010 Feb 12.

Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.

Sung B, Park B, Yadav VR, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

b-actin blot in Fig. 1D is the same image as JNK blot in Fig. 5B, stretched vertically.

Fig. 5D - scRNA group, "medium" and "trail" images (1st and 3rd images in this row) are the same.

Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.

2012-02-11T04:28:00.004+09:00

Cancer Res. 2010 Mar 1;70(5):1951-9. Epub 2010 Feb 16.

Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.

Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, Liu M.

Source

Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

Fig 2B - VEGF image is identical to Fig. 4B of PMID 19567671 from 2009.

Fig. 2C - VEGF image is the same as Fig. 4C of PMID 19567671 from 2009

Fi.g 3A - control image is the same as Fi.g 3A of 19567671... AND the same as Fi.g 2B of 21427164

Fig. 5B - p70S6K1 blot, is identical to S6K blot in Figure 6C of PMID 19567671
This same S6K blot was also used again, in Fig. 6C of this paper.

Fig. 6B - same b-actin loading control used for the dose response in top panel, and time course in lower panel.

Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins.

2012-02-11T04:27:00.001+09:00

Mol Cancer Ther. 2010 Apr;9(4):856-68. Epub 2010 Apr 6.

Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins.

Prasad S, Ravindran J, Sung B, Pandey MK, Aggarwal BB.

Source

Houston, TX, 77030, USA.

Fig. 1B - Garcinol and Garcinol plus TRAIL - some cloned areas of the images between 2 panels.

Fig. 6B, top right, Garcinol... the three cells on the right side of the image have been duplicated in the panel.

Fig. 4C - DR4 blot has horizontal seams, bands pasted in.

Crotepoxide chemosensitizes tumor cells through inhibition of expression of proliferation, invasion, and angiogenic proteins linked to proinflammatory pathway.

2012-02-11T04:13:00.000+09:00

J Biol Chem. 2010 Aug 27;285(35):26987-97. Epub 2010 Jun 23.

Crotepoxide chemosensitizes tumor cells through inhibition of expression of proliferation, invasion, and angiogenic proteins linked to proinflammatory pathway.

Prasad S, Yadav VR, Sundaram C, Reuter S, Hema PS, Nair MS, Chaturvedi MM, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Fig. 2D - something erased above the bands?

Fig. 5B - b-actin blot on left and right sides is the same, flipped horizontally.

Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake.

2012-02-11T04:10:00.003+09:00

Biochem Pharmacol. 2010 Oct 1;80(7):1021-32. Epub 2010 Jun 23.

Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake.

Yadav VR, Prasad S, Kannappan R, Ravindran J, Chaturvedi MM, Vaahtera L, Parkkinen J, Aggarwal BB.

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 143, Houston, TX 77030, USA.

Fig. 1. CDC lane in panel A, and left lane in panel C, are cloned.

Fig. 2A - CD and CDC portions of blot (left and right sides), b-actin controls are the same blot.

Fig. 5A - Curcumin 30 min left panel (green cells) is the same as CDC 45 min. right panel (green cells). Also similarities here with Fi.g 2 of PMID 19735646. This paper is cyclodetran-conjugated curcumin, and the other paper is nanoparticle curcumin - many overlapping images between the 2 papers.

1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

2012-02-11T03:00:00.002+09:00

Carcinogenesis. 2011 Jun;32(6):904-12. Epub 2011 Mar 22.

1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB, Liu M.

Source

Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China. xfpang@bio.ecnu.edu.cn

Fi.g 1B - control image is identical to control in Fi.g 3A from PMID 19567671 (from 2009)

Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis.

2012-02-11T02:58:00.002+09:00

Cancer Prev Res (Phila). 2011 Jul;4(7):1084-94. Epub 2011 Apr 13.

Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis.

Prasad S, Pandey MK, Yadav VR, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Fi.g 2A - p-STAT3 blot, left lane has circular outline, pasted in band.

Fig. 5C - right panel - seams above and below pSTAT3 blot.

Fig. 5D - SHP-1 siRNA, 1% panel right side, and 34% panel left side are cloned.

Bharangin, a diterpenoid quinonemethide, abolishes constitutive and inducible nuclear factor-κB (NF-κB) activation by modifying p65 on cysteine 38 residue and reducing inhibitor of nuclear factor-κB α kinase activation, leading to suppression of NF-κB-regulated gene expression and sensitization of tumor cells to chemotherapeutic agents.

2012-02-11T02:56:00.002+09:00

Mol Pharmacol. 2011 Nov;80(5):769-81. Epub 2011 Jul 27.

Bharangin, a diterpenoid quinonemethide, abolishes constitutive and inducible nuclear factor-κB (NF-κB) activation by modifying p65 on cysteine 38 residue and reducing inhibitor of nuclear factor-κB α kinase activation, leading to suppression of NF-κB-regulated gene expression and sensitization of tumor cells to chemotherapeutic agents.

Gupta SC, Kannappan R, Kim J, Rahman GM, Francis SK, Raveendran R, Nair MS, Das J, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.

Fi.g 3B - PARP control blot is the same in left/right panels, flipped horizontally

Suppression of pro-inflammatory and proliferative pathways by diferuloylmethane (curcumin) and its analogues dibenzoylmethane, dibenzoylpropane, and dibenzylideneacetone: role of Michael acceptors and Michael donors.

2012-02-11T02:55:00.001+09:00

Biochem Pharmacol. 2011 Dec 15;82(12):1901-9. Epub 2011 Sep 8.

Suppression of pro-inflammatory and proliferative pathways by diferuloylmethane (curcumin) and its analogues dibenzoylmethane, dibenzoylpropane, and dibenzylideneacetone: role of Michael acceptors and Michael donors.

Anand P, Sung B, Kunnumakkara AB, Rajasekharan KN, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, Unit 1950, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

Fig. 6B/6E b-actin loading controls the same, flipped horizontal

3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IκBα kinase, leading to down-regulation of nuclear factor-κB (NF-κB)-regulated gene products and sensitization of tumor cells.

2012-02-11T02:52:00.000+09:00

J Biol Chem. 2012 Jan 2;287(1):245-56. Epub 2011 Nov 7.

3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IκBα kinase, leading to down-regulation of nuclear factor-κB (NF-κB)-regulated gene products and sensitization of tumor cells.

Yadav VR, Prasad S, Gupta SC, Sung B, Phatak SS, Zhang S, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Fig 2C b-actin blot has seams (enhance contrast and you will see it)

Fig. 2G/H - IKKa blot in panel G is IKKb blot from panel H flipped horizontally. IKKb blot in panel G is IKKa blot from panel H flipped horizontally.

Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of deathreceptors.

2012-02-09T00:12:00.002+09:00

Mol Cancer Ther. 2010 Aug;9(8):2196-207. Epub 2010 Aug 3.

Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of deathreceptors.

Kannappan R, Ravindran J, Prasad S, Sung B, Yadav VR, Reuter S, Chaturvedi MM, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Fig. 6C contains LOTS of duplicated sections. I can see at least 8 separate examples where parts of one panel are copied/pasted/flipped/rotated from other panels.

Celastrol suppresses invasion of colon and pancreatic cancer cells through thedownregulation of expression of CXCR4 chemokine receptor.

2012-02-09T00:11:00.003+09:00

J Mol Med (Berl). 2010 Dec;88(12):1243-53. Epub 2010 Aug 27.

Celastrol suppresses invasion of colon and pancreatic cancer cells through thedownregulation of expression of CXCR4 chemokine receptor.

Yadav VR, Sung B, Prasad S, Kannappan R, Cho SG, Liu M, Chaturvedi MM, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.

2012-02-08T23:54:00.000+09:00

Mol Cancer Res. 2010 Oct;8(10):1425-36. Epub 2010 Sep 8.

Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.

Reuter S, Prasad S, Phromnoi K, Kannappan R, Yadav VR, Aggarwal BB.
Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Source

Fig. 2A, 6A - "embelin day 1" in Fig.2A and "+ NBP (Medium)" in Fig. 6A are the same image

Source

Fig. 2A - embelin day 3 and embelin days 4 are the same image, rotated 180 degrees.

Source

Fig. 5E - cleaved caspase blot, square seams around lane 4, pasted in?

Source

ROS and CHOP are critical for dibenzylideneacetone to sensitizetumor cells to TRAIL through induction of death receptors anddownregulation of cell survival proteins.

2012-02-08T22:50:00.001+09:00

Cancer Res. 2011 Jan 15;71(2):538-49. Epub 2010 Dec 2.

ROS and CHOP are critical for dibenzylideneacetone to sensitizetumor cells to TRAIL through induction of death receptors anddownregulation of cell survival proteins.

Prasad S, Yadav VR, Ravindran J, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.

Fig. 3C, 4A, 4B - beta-Actin images are the same.

Fig. 3A DR5 blot, left 2 bands have circular shadow, pasted in band.

Fig. 5C - TRAIL image is similar to Fig. 4B in Cancer Res. 2011;Jan 15:71(2):538-49.

Fig. 6B - Bcl2 blot, circular shadows in lanes 2 & 3, bands basted in.

Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK.

2012-02-08T21:57:00.000+09:00

J Biol Chem. 2011 Feb 18;286(7):5546-57. Epub 2010 Dec 14.

Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK.

Prasad S, Yadav VR, Kannappan R, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Fig.2 E

Fig. 3A DR5 blot, left 2 bands have circular shadow, pasted in band.

Fig. 4D - seams in DR5 blot (enhance contrast to see it).

Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.

2012-02-08T21:33:00.001+09:00

Toxicology. 2006 Nov 10;228(1):1-15. Epub 2006 Aug 12.

Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells.

Sharma C, Kaur J, Shishodia S, Aggarwal BB, Ralhan R.

Source

Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.

Fig. 2 has duplicated panels (Cur+STE AMOS vs. Cur + TNF AMOS)

Fig. 7. pixelated, but evidence of splicing

Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells.

2012-02-08T21:15:00.003+09:00

Mol Cancer Res. 2007 Sep;5(9):943-55.

Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells.

Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 143, Houston, TX 77030, USA.

FIGURE 4.

A. Ursolic acid enhances the expression of proapoptotic Bax and Bak proteins. U266 cells (2 × 10⁶/mL) were treated with 50 μmol/L ursolic acid for the indicated time intervals, after which whole-cell extracts were prepared and 30-μg portions of those extracts were resolved on 10% SDS-PAGE and probed against Bax and Bak antibodies. The same blots were stripped and reprobed with β-actin antibody to verify equal protein loading. B. Ursolic acid suppresses STAT3 regulated antiapoptotic gene products. U266 cells (2 × 10⁶/mL) were treated with 50 μmol/L ursolic acid for the indicated time intervals, after which whole-cell extracts were prepared and 30-μg portions of those extracts were resolved on 10% SDS-PAGE, membrane sliced according to molecular weight, and probed against cyclin D1, Bcl-2, Bcl-X_L, survivin, and VEGF antibodies. The same blots were stripped and reprobed with β-actin antibody to verify equal protein loading. C.Ursolic acid suppresses the expression of Mcl-1 protein. U266 cells (2 × 10⁶/mL) were treated with 50 μmol/L ursolic acid for the indicated time intervals, after which whole-cell extracts were prepared and 30-μg portions of those extracts were resolved on 10% SDS-PAGE and probed against Mcl-1 antibodies. The same blots were stripped and reprobed with β-actin antibody to verify equal protein loading. D. Ursolic acid inhibits gene expression. U266 cells (4 × 10⁶/mL) were treated with ursolic acid (50 μmol/L) for the indicated time points, and total RNA was extracted and examined for expression ofcyclin D1, Bcl-2, and Bcl-x_L by RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control to show equal RNA loading.

Figure 6A - Control, UA, and Bortezomib images are the same as Control, Capsaicin, Velcade
images in Figure 6A and 6B of PMID 17505005

Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumolleads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis inleukemia cells.

2012-02-07T22:40:00.001+09:00

Blood. 2009 Feb 26;113(9):2003-13. Epub 2008 Oct 24.

Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumolleads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis inleukemia cells.

Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.

2012-02-07T22:36:00.002+09:00

Clin Cancer Res. 2007 May 15;13(10):3024-32.

Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.

Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Fig. 2C -STAT 3 loading control is actually the b-acting loading control from Fig. 4B of 20103603. (3 years apart, and he's using the same image for 2 totally different things. Also, there's evidence of material being erased from the top-right corner of the image on both cases - that's how we know they are the same!)

Fig. 6 - Medium and Capsaicin images in 6A and 6B are the same (numbers below are different). Also these images are identical to PMID 17855663 Fig. 6A, but different agent added (ursolic acid).

Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappa B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis.

2012-02-07T22:33:00.000+09:00

Mol Cancer Ther. 2008 Oct;7(10):3306-17.

Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappa B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis.

Kunnumakkara AB, Ichikawa H, Anand P, Mohankumar CJ, Hema PS, Nair MS, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Unit 143, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Fig. 2B and 4B - same b-actin loading controls.

Fig. 2D - compare to images of Fig. 5A in PMID 18952893.

Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1.

2012-02-07T22:20:00.000+09:00

Cancer Res. 2008 Jun 1;68(11):4406-15.

Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1.

Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Fig. 4C - enhance the contrast on the lower image - there's a splice between the NC and PC lanes.